IDEXX Laboratories Financials
IDEXX Laboratories (IDXX) reported $4.3B in revenue for fiscal year 2025, up 10.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
High-margin, low-capex growth is converting more revenue into cash, funding deleveraging and outsized buybacks.
From FY2023 to FY2025, operating margin rose from30.0% to31.6% even as R&D spending increased from$191M to$251M , so the margin lift was not achieved by cutting future-facing investment. In FY2025, operating cash flow of$1.18B exceeded$1.06B of net income, showing that the earnings improvement is arriving as cash rather than staying trapped in accruals.
This is a capital-light operating model: FY2025 capital spending was only
The balance sheet is being shaped more by capital allocation than by financing pressure: long-term debt fell from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of IDEXX Laboratories's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
IDEXX Laboratories has an operating margin of 31.6%, meaning the company retains $32 of operating profit per $100 of revenue. This strong profitability earns a score of 96/100, reflecting efficient cost management and pricing power. This is up from 28.9% the prior year.
IDEXX Laboratories's revenue grew 10.4% year-over-year to $4.3B, a solid pace of expansion. This earns a growth score of 61/100.
IDEXX Laboratories carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 78/100, indicating a strong balance sheet with room for future borrowing.
IDEXX Laboratories's current ratio of 1.23 indicates adequate short-term liquidity, earning a score of 30/100. The company can meet its near-term obligations, though with limited headroom.
IDEXX Laboratories converts 24.6% of revenue into free cash flow ($1.1B). This strong cash generation earns a score of 89/100.
IDEXX Laboratories earns a strong 66.0% return on equity (ROE), meaning it generates $66 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 98/100. This is up from 55.6% the prior year.
IDEXX Laboratories scores 20.17, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($43.0B) relative to total liabilities ($1.7B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
IDEXX Laboratories passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, IDEXX Laboratories generates $1.12 in operating cash flow ($1.2B OCF vs $1.1B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
IDEXX Laboratories earns $35.01 in operating income for every $1 of interest expense ($1.4B vs $38.9M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
IDEXX Laboratories generated $4.3B in revenue in fiscal year 2025. This represents an increase of 10.4% from the prior year.
IDEXX Laboratories's EBITDA was $1.5B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.6% from the prior year.
IDEXX Laboratories reported $1.1B in net income in fiscal year 2025. This represents an increase of 19.3% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
IDEXX Laboratories generated $1.1B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 30.8% from the prior year.
IDEXX Laboratories held $180.1M in cash against $374.8M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
IDEXX Laboratories's gross margin was 61.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.8 percentage points from the prior year.
IDEXX Laboratories's operating margin was 31.6% in fiscal year 2025, reflecting core business profitability. This is up 2.7 percentage points from the prior year.
IDEXX Laboratories's net profit margin was 24.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.8 percentage points from the prior year.
IDEXX Laboratories's ROE was 66.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 10.3 percentage points from the prior year.
Capital Allocation
IDEXX Laboratories invested $251.2M in research and development in fiscal year 2025. This represents an increase of 14.3% from the prior year.
IDEXX Laboratories spent $1.2B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 45.4% from the prior year.
IDEXX Laboratories invested $124.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 3.1% from the prior year.
IDXX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.6B | $4.3B+10.4% | $3.9B+6.5% | $3.7B+8.7% | $3.4B+4.7% | $3.2B+18.8% | $2.7B+12.5% | $2.4B+8.8% | $2.2B+12.4% | $2.0B+10.9% | $1.8B+10.8% | $1.6B+7.8% | $1.5B+7.9% | $1.4B+6.5% | $1.3B+6.1% | $1.2B |
| Cost of Revenue | $1.7B | $1.6B+8.3% | $1.5B+3.2% | $1.5B+7.9% | $1.4B+2.8% | $1.3B+16.8% | $1.1B+9.1% | $1.0B+7.2% | $971.7M+11.5% | $871.7M+9.0% | $800.0M+12.4% | $711.6M+6.3% | $669.7M+7.9% | $620.9M+4.5% | $594.2M+3.8% | $572.2M |
| Gross Profit | $2.8B | $2.7B+11.8% | $2.4B+8.6% | $2.2B+9.3% | $2.0B+6.1% | $1.9B+20.3% | $1.6B+15.0% | $1.4B+10.0% | $1.2B+13.1% | $1.1B+12.5% | $975.4M+9.6% | $890.3M+9.1% | $816.1M+7.9% | $756.1M+8.1% | $699.1M+8.1% | $646.5M |
| R&D Expenses | $261.5M | $251.2M+14.3% | $219.8M+15.1% | $191.0M-25.1% | $254.8M+58.3% | $161.0M+14.0% | $141.2M+6.0% | $133.2M+13.0% | $117.9M+8.0% | $109.2M+8.0% | $101.1M+1.4% | $99.7M+1.4% | $98.3M+11.7% | $88.0M+7.3% | $82.0M+7.9% | $76.0M |
| SG&A Expenses | $450.5M | $404.8M-8.5% | $442.3M+31.7% | $335.8M+2.9% | $326.2M+5.4% | $309.7M+2.9% | $300.8M+15.1% | $261.3M+6.7% | $244.9M+10.9% | $220.9M+6.7% | $207.0M+13.4% | $182.5M+5.0% | $173.9M+10.2% | $157.9M+14.7% | $137.6M+6.4% | $129.4M |
| Operating Income | $1.5B | $1.4B+20.5% | $1.1B+2.8% | $1.1B+22.1% | $898.8M-3.6% | $932.0M+34.2% | $694.5M+25.6% | $552.8M+12.5% | $491.3M+19.0% | $413.0M+17.9% | $350.2M+16.8% | $299.9M+15.2% | $260.3M-2.4% | $266.8M+1.6% | $262.6M+11.1% | $236.2M |
| Interest Expense | $37.8M | $38.9M+24.5% | $31.2M-25.0% | $41.6M+4.3% | $39.9M+33.7% | $29.8M-10.0% | $33.1M+6.7% | $31.1M-10.6% | $34.7M-6.7% | $37.2M+16.2% | $32.0M+9.6% | $29.2M+89.5% | $15.4M+186.5% | $5.4M+40.0% | $3.8M+8.5% | $3.5M |
| Income Tax | $284.8M | $264.7M+19.3% | $222.0M+2.7% | $216.1M+19.5% | $180.9M+14.6% | $157.8M+97.6% | $79.9M-15.4% | $94.4M+17.0% | $80.7M-31.5% | $117.8M+18.0% | $99.8M+23.2% | $81.0M+25.4% | $64.6M-14.4% | $75.5M-8.3% | $82.3M+13.3% | $72.7M |
| Net Income | $1.1B | $1.1B+19.3% | $887.9M+5.1% | $845.0M+24.4% | $679.1M-8.8% | $744.8M+28.0% | $581.8M+36.0% | $427.7M+13.4% | $377.0M+43.3% | $263.1M+18.5% | $222.0M+15.6% | $192.1M+5.6% | $181.9M-3.1% | $187.8M+5.3% | $178.3M+10.2% | $161.8M |
Not reported in any period shown, so not listed: EPS (Diluted).
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IDXX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.4B+1.7% | $3.3B+1.0% | $3.3B+18.7% | $2.7B+12.7% | $2.4B+6.2% | $2.3B+25.2% | $1.8B+19.2% | $1.5B-10.3% | $1.7B+11.9% | $1.5B+3.8% | $1.5B+6.6% | $1.4B+12.5% | $1.2B+11.5% | $1.1B+7.1% | $1.0B |
| Current Assets | $1.4B+1.0% | $1.4B-6.4% | $1.5B+35.7% | $1.1B+15.3% | $955.7M-10.1% | $1.1B+56.4% | $679.6M+3.9% | $654.2M-32.7% | $972.0M+14.9% | $845.6M+2.9% | $821.6M+8.2% | $759.4M+16.3% | $652.7M+14.6% | $569.5M+8.6% | $524.2M |
| Cash & Equivalents | $180.1M-37.5% | $288.3M-36.5% | $453.9M+303.3% | $112.5M-22.1% | $144.5M-62.4% | $383.9M+325.0% | $90.3M-27.0% | $123.8M-34.0% | $187.7M+21.2% | $154.9M+20.1% | $129.0M-60.0% | $322.5M+15.6% | $279.1M+24.6% | $224.0M+21.8% | $183.9M |
| Inventory | $377.8M-1.1% | $381.9M+0.4% | $380.3M+3.4% | $367.8M+36.7% | $269.0M+28.2% | $209.9M+7.6% | $195.0M+12.5% | $173.3M+5.5% | $164.3M+4.0% | $158.0M-16.3% | $188.8M+17.8% | $160.3M+20.2% | $133.4M-5.3% | $140.9M+5.9% | $133.1M |
| Accounts Receivable | $552.4M+16.6% | $473.6M+3.5% | $457.4M+14.2% | $400.6M+8.8% | $368.3M+11.1% | $331.4M+23.1% | $269.3M+8.2% | $248.9M+6.1% | $234.6M+14.7% | $204.5M+8.6% | $188.3M+23.6% | $152.4M-3.6% | $158.0M+14.3% | $138.3M-2.1% | $141.3M |
| Goodwill | $414.0M+2.2% | $405.1M+10.7% | $366.0M+1.2% | $361.8M+0.7% | $359.3M+47.7% | $243.3M+1.5% | $239.7M+11.8% | $214.5M+7.3% | $199.9M+12.1% | $178.2M-0.4% | $178.9M-3.0% | $184.4M+2.2% | $180.5M+3.2% | $175.0M+1.4% | $172.6M |
| Total Liabilities | $1.7B+2.8% | $1.7B-4.4% | $1.8B-17.0% | $2.1B+22.4% | $1.7B+5.1% | $1.7B+0.4% | $1.7B+7.0% | $1.5B-12.5% | $1.8B+7.8% | $1.6B+5.1% | $1.6B+23.1% | $1.3B+77.8% | $712.3M+52.4% | $467.3M-4.9% | $491.2M |
| Current Liabilities | $1.1B+7.6% | $1.1B+12.2% | $951.5M-23.0% | $1.2B+61.8% | $763.6M+31.0% | $582.8M-19.7% | $725.3M-5.9% | $770.4M-23.3% | $1.0B+7.5% | $934.6M+9.1% | $856.8M+4.4% | $820.9M+71.6% | $478.4M+17.7% | $406.3M-7.0% | $436.9M |
| Long-Term Debt | $374.8M-16.7% | $449.8M-27.8% | $622.9M-10.3% | $694.4M-10.4% | $775.2M-9.7% | $858.5M+22.8% | $698.9M+16.1% | $601.8M-0.8% | $606.6M+2.2% | $593.7M-0.6% | $597.1M+70.6% | $350.0M+131.2% | $151.4M+5953.3% | $2.5M-26.8% | $3.4M |
| Total Equity | $1.6B+0.6% | $1.6B+7.5% | $1.5B+143.9% | $608.7M-11.8% | $690.0M+9.2% | $632.1M+256.2% | $177.5M+1965.6% | -$9.5M+82.4% | -$54.1M+50.1% | -$108.4M-28.8% | -$84.1M-171.6% | $117.5M-77.3% | $518.2M-18.6% | $636.2M+17.9% | $539.6M |
| Retained Earnings | $6.4B+19.9% | $5.3B+20.0% | $4.4B+23.5% | $3.6B+23.3% | $2.9B+34.2% | $2.2B+36.3% | $1.6B+36.6% | $1.2B+45.3% | $803.5M+48.7% | $540.4M+69.7% | $318.4M-81.0% | $1.7B+12.2% | $1.5B+14.4% | $1.3B+15.8% | $1.1B |
IDXX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.4B | $1.2B+27.2% | $929.0M+2.5% | $906.5M+66.9% | $543.0M-28.1% | $755.5M+16.6% | $648.1M+41.1% | $459.2M+14.8% | $400.1M+7.2% | $373.3M+10.1% | $338.9M+52.8% | $221.8M-6.0% | $235.8M-4.1% | $246.0M+10.6% | $222.4M+2.1% | $217.9M |
| Capital Expenditures | $117.2M | $124.7M+3.1% | $120.9M-9.5% | $133.6M-10.2% | $148.8M+24.5% | $119.5M+11.8% | $107.0M-31.0% | $155.0M+33.9% | $115.8M+55.6% | $74.4M+14.8% | $64.8M-21.9% | $82.9M+37.0% | $60.5M-22.0% | $77.6M+34.7% | $57.6M+16.0% | $49.7M |
| Free Cash Flow | $1.3B | $1.1B+30.8% | $808.1M+4.6% | $772.9M+96.1% | $394.1M-38.0% | $636.0M+17.5% | $541.1M+77.9% | $304.2M+7.0% | $284.3M-4.9% | $298.9M+9.0% | $274.2M+97.4% | $138.9M-20.8% | $175.3M+4.1% | $168.4M+2.2% | $164.8M-2.0% | $168.2M |
| Investing Cash Flow | -$132.0M | -$136.2M+34.2% | -$207.1M-65.3% | -$125.3M+35.9% | -$195.3M+33.3% | -$293.0M-167.9% | -$109.4M+46.8% | -$205.5M-248.3% | $138.6M+199.9% | -$138.7M | N/A | N/A | -$80.4M+6.6% | -$86.1M-48.0% | -$58.1M+38.3% | -$94.2M |
| Financing Cash Flow | -$1.2B | -$1.2B-32.7% | -$878.1M-98.7% | -$442.0M-19.2% | -$370.9M+46.8% | -$697.4M-180.7% | -$248.4M+13.3% | -$286.4M+52.1% | -$597.8M-187.4% | -$208.0M | N/A | N/A | -$103.4M-1.0% | -$102.5M+18.3% | -$125.3M-28.4% | -$97.7M |
| Share Buybacks | $1.2B | $1.2B+45.4% | $837.0M+1063.8% | $71.9M-91.2% | $819.7M+9.8% | $746.8M+308.5% | $182.8M-39.4% | $301.7M-18.3% | $369.3M+30.7% | $282.6M-7.1% | $304.1M-24.4% | $402.0M-35.0% | $618.2M+68.1% | $367.8M+178.0% | $132.3M-48.2% | $255.5M |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
IDXX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.8%+0.8pp | 61.0%+1.2pp | 59.8%+0.3pp | 59.5%+0.8pp | 58.8%+0.7pp | 58.0%+1.3pp | 56.7%+0.6pp | 56.1%+0.4pp | 55.7%+0.8pp | 54.9%-0.6pp | 55.6%+0.6pp | 54.9%0.0pp | 54.9%+0.9pp | 54.1%+1.0pp | 53.0% |
| Operating Margin | 31.6%+2.7pp | 28.9%-1.0pp | 30.0%+3.3pp | 26.7%-2.3pp | 29.0%+3.3pp | 25.7%+2.7pp | 23.0%+0.8pp | 22.2%+1.2pp | 21.0%+1.2pp | 19.7%+1.0pp | 18.7%+1.2pp | 17.5%-1.9pp | 19.4%-0.9pp | 20.3%+0.9pp | 19.4% |
| Net Margin | 24.6%+1.8pp | 22.8%-0.3pp | 23.1%+2.9pp | 20.2%-3.0pp | 23.2%+1.7pp | 21.5%+3.7pp | 17.8%+0.7pp | 17.0%+3.7pp | 13.4%+0.9pp | 12.5%+0.5pp | 12.0%-0.2pp | 12.2%-1.4pp | 13.6%-0.1pp | 13.8%+0.5pp | 13.3% |
| Return on Equity | 66.0%+10.3pp | 55.6%-1.3pp | 56.9%-54.6pp | 111.6%+3.6pp | 107.9%+15.9pp | 92.0%-149.0pp | 241.0% | N/A | N/A | N/A | N/A | 154.8%+118.5pp | 36.2%+8.2pp | 28.0%-2.0pp | 30.0% |
| Return on Assets | 31.6%+4.7pp | 27.0%+1.0pp | 25.9%+1.2pp | 24.7%-5.8pp | 30.6%+5.2pp | 25.4%+2.0pp | 23.3%-1.2pp | 24.5%+9.2pp | 15.4%+0.8pp | 14.5%+1.5pp | 13.0%-0.1pp | 13.1%-2.1pp | 15.3%-0.9pp | 16.2%+0.5pp | 15.7% |
| Current Ratio | 1.23-0.1x | 1.31-0.3x | 1.57+0.7x | 0.89-0.4x | 1.25-0.6x | 1.82+0.9x | 0.94+0.1x | 0.85-0.1x | 0.97+0.1x | 0.90-0.1x | 0.960.0x | 0.93-0.4x | 1.360.0x | 1.40+0.2x | 1.20 |
| Debt-to-Equity | 0.230.0x | 0.28-0.1x | 0.42-0.7x | 1.140.0x | 1.12-0.2x | 1.36-2.6x | 3.94 | N/A | N/A | N/A | N/A | 2.98+2.7x | 0.29+0.3x | 0.000.0x | 0.01 |
| FCF Margin | 24.6%+3.8pp | 20.7%-0.4pp | 21.1%+9.4pp | 11.7%-8.1pp | 19.8%-0.2pp | 20.0%+7.3pp | 12.6%-0.2pp | 12.8%-2.3pp | 15.2%-0.3pp | 15.4%+6.8pp | 8.7%-3.1pp | 11.8%-0.4pp | 12.2%-0.5pp | 12.7%-1.1pp | 13.8% |
Similar Companies
Where IDEXX Laboratories Ranks
Frequently Asked Questions
What is IDEXX Laboratories's annual revenue?
IDEXX Laboratories (IDXX) reported $4.3B in total revenue for fiscal year 2025. This represents a 10.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is IDEXX Laboratories's revenue growing?
IDEXX Laboratories (IDXX) revenue grew by 10.4% year-over-year, from $3.9B to $4.3B in fiscal year 2025.
Is IDEXX Laboratories profitable?
Yes, IDEXX Laboratories (IDXX) reported a net income of $1.1B in fiscal year 2025, with a net profit margin of 24.6%.
What is IDEXX Laboratories's EBITDA?
IDEXX Laboratories (IDXX) had EBITDA of $1.5B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does IDEXX Laboratories have?
As of fiscal year 2025, IDEXX Laboratories (IDXX) had $180.1M in cash and equivalents against $374.8M in long-term debt.
What is IDEXX Laboratories's gross margin?
IDEXX Laboratories (IDXX) had a gross margin of 61.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is IDEXX Laboratories's operating margin?
IDEXX Laboratories (IDXX) had an operating margin of 31.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is IDEXX Laboratories's net profit margin?
IDEXX Laboratories (IDXX) had a net profit margin of 24.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is IDEXX Laboratories's return on equity (ROE)?
IDEXX Laboratories (IDXX) has a return on equity of 66.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is IDEXX Laboratories's free cash flow?
IDEXX Laboratories (IDXX) generated $1.1B in free cash flow during fiscal year 2025. This represents a 30.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is IDEXX Laboratories's operating cash flow?
IDEXX Laboratories (IDXX) generated $1.2B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are IDEXX Laboratories's total assets?
IDEXX Laboratories (IDXX) had $3.4B in total assets as of fiscal year 2025, including both current and long-term assets.
What are IDEXX Laboratories's capital expenditures?
IDEXX Laboratories (IDXX) invested $124.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does IDEXX Laboratories spend on research and development?
IDEXX Laboratories (IDXX) invested $251.2M in research and development during fiscal year 2025.
What is IDEXX Laboratories's current ratio?
IDEXX Laboratories (IDXX) had a current ratio of 1.23 as of fiscal year 2025, which is considered adequate.
What is IDEXX Laboratories's debt-to-equity ratio?
IDEXX Laboratories (IDXX) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is IDEXX Laboratories's return on assets (ROA)?
IDEXX Laboratories (IDXX) had a return on assets of 31.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is IDEXX Laboratories's Altman Z-Score?
IDEXX Laboratories (IDXX) has an Altman Z-Score of 20.17, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is IDEXX Laboratories's Piotroski F-Score?
IDEXX Laboratories (IDXX) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are IDEXX Laboratories's earnings high quality?
IDEXX Laboratories (IDXX) has an earnings quality ratio of 1.12x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can IDEXX Laboratories cover its interest payments?
IDEXX Laboratories (IDXX) has an interest coverage ratio of 35.01x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is IDEXX Laboratories?
IDEXX Laboratories (IDXX) scores 75 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.